bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
Company profile
Ticker
BCYC
Exchange
Website
CEO
Kevin Lee
Employees
Location
Fiscal year end
Industry (SIC)
Former names
BICYCLE THERAPEUTICS Ltd
SEC CIK
BCYC stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
S-8
Registration of securities for employees
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
20 Feb 24
8-K
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
14 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Latest ownership filings
SC 13D
BAKER BROS. ADVISORS LP
18 Apr 24
3
JULIAN BAKER
18 Apr 24
4
Michael Charles Ferguson Hannay
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
4
Kevin Lee
5 Apr 24
4
Michael Skynner
5 Apr 24
4
Alistair Milnes
5 Apr 24
4
Nigel Crockett
5 Apr 24
4
Nicholas Keen
5 Apr 24
4
Travis Alvin Thompson
5 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm |
Cash burn (monthly) | (no burn) | (no burn) | 16.93 mm | 13.99 mm | 341.67 k | 3.64 mm |
Cash used (since last report) | n/a | n/a | 113.07 mm | 93.45 mm | 2.28 mm | 24.29 mm |
Cash remaining | n/a | n/a | 459.56 mm | 479.18 mm | 570.35 mm | 548.34 mm |
Runway (months of cash) | n/a | n/a | 27.1 | 34.2 | 1669.3 | 150.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 24 |
Closed positions | 9 |
Increased positions | 36 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 634.19 bn |
Total shares | 36.99 mm |
Total puts | 73.80 k |
Total calls | 27.70 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
Paradigm Biocapital Advisors | 3.64 mm | $73.17 bn |
Deep Track Capital | 3.49 mm | $70.12 bn |
First Light Asset Management | 2.07 mm | $41.60 bn |
JEF Jefferies Financial | 1.95 mm | $39.14 bn |
MS Morgan Stanley | 1.62 mm | $32.58 bn |
SVLSF V | 1.56 mm | $54.41 mm |
GSK GSK | 1.53 mm | $39.40 mm |
Point72 Asset Management | 1.30 mm | $26.11 bn |
Braidwell | 1.29 mm | $25.91 bn |
Tybourne Capital Management | 1.28 mm | $25.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Michael Charles Ferguson Hannay | Ordinary Shares | Sell | Dispose S | No | No | 22.49 | 257 | 5.78 k | 22,891 |
3 Apr 24 | Lee Kevin | Ordinary Shares | Sell | Dispose S | No | No | 23.81 | 3,158 | 75.19 k | 387,270 |
3 Apr 24 | Skynner Michael | Ordinary Shares | Sell | Dispose S | No | No | 23.81 | 955 | 22.74 k | 94,884 |
3 Apr 24 | Alistair Milnes | Ordinary Shares | Sell | Dispose S | No | No | 23.81 | 955 | 22.74 k | 72,241 |
News
Expert Ratings For Bicycle Therapeutics
10 Apr 24
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
10 Apr 24
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
21 Feb 24
Canaccord Genuity Reiterates Buy on Bicycle Therapeutics, Maintains $60 Price Target
21 Feb 24
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
21 Feb 24
Press releases
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
5 Mar 24
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
28 Feb 24
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
7 Feb 24